Added to YB: 2026-10-08
Pitch date: 2026-10-04
BCRX [bullish]
BioCryst Pharmaceuticals, Inc.
-1.47%
current return
Author Info
No bio for this author
Company Info
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Market Cap
$2.1B
Pitch Price
$8.17
Price Target
N/A
Dividend
N/A
EV/EBITDA
5.86
P/E
-4.83
EV/Sales
2.72
Sector
Biotechnology
Category
growth
Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - BioCryst Pharmaceuticals, Inc.
BCRX: BioCryst, at $8.15, is a rare-disease commercial franchise whose thesis rests on ORLADEYO’s oral prophylaxis opportunity in hereditary angioedema; the thesis does not depend on a takeover. Physicians can move appropriate patients to oral therapy without new site-of-care infrastructure. Growth depends on sustained patient adoption and management’s ability to reinvest franchise cash flow productively through pipeline development, partnerships or acquisitions.
Read full article (1 min)